

Program

11th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy

March 24 – 27, 2010

Wednesday, March 24, 2010

14:00 – 18:00	Registration at the International Conference Centre (CICG)
16:30 – 17:00	Welcome address: Ezio Giacobini and Gabriel Gold, Organizers René Rizzoli , Head of the Department of Rehabilitation and Geriatrics, Geneva University Hospitals Bernard Gruson , General Director, Geneva University Hospitals Jean-Louis Carpentier , Dean, Faculty of Medicine, University of Geneva J. Kevin Dorsey , Dean, Southern Illinois University School of Medicine, Springfield Minister of Health of the Republic and Swiss Canton of Geneva
17:00 – 18:00	<i>Opening Lecture:</i> Richard Frackowiak (Lausanne, Switzerland) London Taxi Drivers, Hippocampus and Alzheimer Disease
18:00 – 19:30	Welcome Reception: CICG

Thursday, March 25, 2010

Room A

08:15 – 08:35	<i>State of the art lecture:</i> Serge Gauthier (Montreal, Canada) Why so few drugs for AD? The question
---------------	--

Why so Few Drugs for AD?

Chairs: Serge Gauthier and Lon Schneider

08:35 – 08:55	Robert Becker (South Freeport, USA) Why so few AD drugs? Could methods be failing drugs?
08:55 – 09:15	Cristina Sampaio (Lisbon, Portugal) Regulatory view point
09:15 – 09:35	Lon Schneider (Los Angeles, USA) The clinical trial: wrong target or wrong design?
09:35 – 09:55	Eric Siemers (Indianapolis, USA) Why so few drugs for AD? The drug company viewpoint

09:55 – 10:25 Break

10:25 – 10:45	<i>State of the art lecture:</i> Roger Nitsch (Zurich, Switzerland) Immunization: the future of AD therapy
---------------	--

The Culprits: Monomers, Dimers, Trimers and Other Oligomers

Chairs: Roger Nitsch and Karen Ashe

10:45 – 11:05	Karen Ashe (Minneapolis, USA) Fluctuating patterns of A-beta oligomers in AD
11:05 – 11:25	Stephen Strittmatter (New Haven, USA) Role of cellular prion protein in AD
11:25 – 11:45	Nivaldo Inestrosa (Santiago, Chile) Amyloid beta oligomers at brain synapses
11:45 – 12:05	William Klein (Chicago, USA) Synaptotoxic A-beta oligomers (ADDLs): A molecular basis for the cause, diagnosis, and treatment of Alzheimer disease

12:05 – 13:30 Lunch

From Bench to Bedside: Rationale for Early Diagnosis and Treatment in Alzheimer's Disease

Chair: Dale Schenk

- 13:30 – 13:35 Introduction
13:35 – 14:00 **Christian Haass** (Munich, Germany)
In vivo analysis of amyloid A-beta peptide inhibition and tau mediated neurotoxicity
14:00 – 14:25 **David Teplow** (Los Angeles, USA)
A-beta oligomers: Therapeutic targets in AD
14:25 – 14:50 **Jean-François Dartigues** (Bordeaux, France)
Identifying AD early: Is it possible?
14:50 – 15:10 Questions and answers
(mini-symposium supported by Elan)

15:10 – 15:40 Break

Active and Passive Immunization

Chairs: Bengt Winblad and Dale Schenk

- 15:40 – 16:00 **Dale Schenk** (South San Francisco, USA)
A-beta immunotherapy: Lessons learned on the role of A-beta in AD
16:00 – 16:20 **Ronald DeMattos** (Indianapolis, USA)
A-beta immunotherapy: tailoring specific biomarkers for clinical development
16:20 – 16:40 **Bengt Winblad** (Stockholm, Sweden)
Immunotherapy in AD: An update of present experience
16:40 – 17:00 **Ronald Black** (Collegeville, USA)
A-beta immunotherapy in AD: Clinical evidence for disease modification

17:20 – 19:00 Reception with poster viewing and discussion

Thursday, March 25, 2010

Room B

- 08:15 – 08:35 *State of the art lecture:* **Jaakov Stern** (New York, USA)
The impact of reserve on AD pathology

Imaging of the Brain: Testing Drug Effects

Chairs: Agneta Nordberg and Hilkka Soininen

- 08:35 – 08:55 **William Klunk** (Pittsburgh, USA)
Amyloid imaging: strengths and weaknesses in drug development
08:55 – 09:15 **Hilkka Soininen** (Kuopio, Finland)
MRI imaging of the brain: testing drug effects
09:15 – 09:35 **William Jagust** (Berkeley, USA)
Imaging in drug development: It's not just amyloid
09:35 – 09:55 **Agneta Nordberg** (Stockholm, Sweden)
Amyloid imaging in the evaluation of new drug therapy in AD

09:55 – 10:25 Break

- 10:25 – 10:45 *State of the art lecture:* **Renaud Du Pasquier** (Lausanne, Switzerland)
Neurocognitive disorders associated with the human immunodeficiency virus

Emerging Novel Therapeutic Targets I

Chairs: Abraham Fisher and Pierre Dayer

- 10:45 – 11:05 **Abraham Fisher** (Ness Ziona, Israel)
M1 muscarinic agonists: A powerful weapon in the anti-AD arsenal
11:05 – 11:25 **Achim Schneeberger** (Vienna, Austria)
Alzheimer AFFITOPE vaccines
11:25 – 11:45 **Israel Hanin** (Tucson, USA)
A-beta anti-aggregants
11:45 – 12:05 **Gerhard Koenig** (Watertown, USA)
Nicotinic compounds for cognitive deficits
(session partially supported by Affiris GmbH, Austria ; EnVivo Pharmaceuticals, USA)

12:05 – 13:30 Lunch

13:30 – 13:50 *State of the art lecture: François Herrmann* (Geneva, Switzerland)
Do intelligent and educated people live longer?

Focusing on Early Diagnosis and Treatment of Alzheimer Disease

Chairs: Steven DeKosky and John Morris

13:50 – 14:10 **Steven DeKosky** (Charlottesville, USA)
Amyloid burden in normal and MCI patients

14:10 – 14:30 **Jean-Marc Orgogozo** (Bordeaux, France)
Identification of predementia AD with neuropsychological tests

14:30 – 14:50 **Christoph Hock** (Zurich, Switzerland)
Immunological features of healthy aging, MCI and Alzheimer disease

14:50 – 15:10 **John Morris** (St. Louis, USA)
Non-demented aging and preclinical Alzheimer disease

15:10 – 15:40 Break

15:40 – 16:00 *State of the art lecture: Dina Zekry* (Geneva, Switzerland)
Oxidative stress in MCI and Alzheimer disease

Prevention of AD

Chairs: Laura Fratiglioni and Bruno Vellas

16:00 – 16:20 **Laura Fratiglioni** (Stockholm, Sweden)
Alzheimer disease: Risk factors and prevention

16:20 – 16:40 **Miia Kivipelto** (Stockholm, Sweden)
Prevention of AD: is it possible? Nordic multi-domain intervention studies

16:40 – 17:00 **Bruno Vellas** (Toulouse, France)
The GuidAge study: New results

17:00 – 17:20 **Patrizia Mecocci** (Perugia, Italy)
Mitochondria: Targets of preventive therapy

17:20 – 19:00 Reception with poster viewing and discussion

Friday, March 26, 2010

Room A

Advances in Neuroimaging for Alzheimer Disease

Chairs: Mike Weiner and Samuel Svensson

08:15 – 08:20 Introduction

08:20 – 08:40 **Michael Weiner** (San Francisco, USA)
Biomarkers for monitoring the progression of AD in clinical trials: The Alzheimer disease neuroimaging initiative

08:40 – 09:00 **Nick Fox** (London, UK)
4D MRI: measuring change for early detection and monitoring of progression

09:00 – 09:20 **Simon Lovestone** (London, UK)
Combinatorial biomarkers of Alzheimer disease and the value of multimodal analysis

09:20 – 09:40 **Eric Reiman** (Phoenix, USA)
(18F)AZD4694 in the symptomatic and pre-symptomatic study of AD

09:40 – 09:55 Discussion
(*mini-symposium supported by AstraZeneca*)

09:55 – 10:25 Break

10:25 – 12:05 **Developing the Next Generation of Treatment**
(*mini-symposium supported by Pfizer*)

12:05 – 13:30 Lunch

Treatment of Alzheimer's Disease – Short Term Benefits and Beyond

Chair: Roy Jones

13:30 – 13:40 **Roy Jones** (Bath, UK)
Introduction

13:40 – 14:10 **Judith Saxton** (Pittsburg, USA)

- 14:10 – 14:40 Important aspects of communication in Alzheimer's disease
David Wilkinson (Southampton, UK)
- 14:40 – 15:10 Short and long-term treatment with memantine in Alzheimer's disease
Roy Jones (Bath, UK)
 Memantine in Alzheimer's disease: Outcomes in real-life
 (*mini-symposium supported by Lundbeck, A/S*)

15:10 – 15:40 Break

Emerging Hypotheses in Cholinesterase Inhibition: Targeted Activity for Optimal Effects

Chair: Lutz Frölich

- 15:40 – 15:45 Chairman's introduction
- 15:45 – 16:10 **Lutz Frölich** (Mannheim, Germany)
 Ambitious dementia treatment with high doses of cholinesterase inhibitors
- 16:10 – 16:35 **Roger Bullock** (Swindon, UK)
 Long-term effects of cholinesterase inhibition – the good, the bad, and the ugly!
- 16:35 – 17:00 **Sultan Darvesh** (Halifax, Canada)
 Possible mechanisms underlying effects of BuChE – emerging hypotheses to spark future research
- 17:00 – 17:15 Questions from the audience
- 17:15 – 17:20 Chairman's conclusions
 (*mini-symposium supported by Novartis*)

Friday, March 26, 2010

Room B

- 08:15 – 08:35 *State of the art lecture: Giancarlo Pepeu* (Florence, Italy)
 The brain cholinergic system is still alive

The Cholinergic System Still Exists

Chairs: Claudio Cuello and Filippo Drago

- 08:35 – 08:55 **Elliott Mufson** (Chicago, USA)
 The cholinergic system in AD: Shifts from survival to death
- 08:55 – 09:15 **Claudio Cuello** (Montreal, Canada)
 The cholinergic system is the most vulnerable to Alzheimer pathology
- 09:15 – 09:35 **Antonio Cattaneo** (Pisa, Italy)
 How to rescue the cholinergic system with NGF
- 09:35 – 09:55 **Maria Eriksdotter Jönhagen** (Stockholm, Sweden)
 Therapy of AD with NGF

09:55 – 10:25 Break

- 10:25 – 10:45 *State of the art lecture: Kaj Blennow* (Mölndal, Sweden)
 Predictive biomarkers of early AD

Preclinical Models of AD and Neural Stem Cells

Chairs: Manfred Windisch and Karl-Heinz Krause

- 10:45 – 11:05 **Manfred Windisch** (Graz, Austria)
 Animal models of Alzheimer disease – their predictive value for drug development
- 11:05 – 11:25 **Kiminobu Sugaya** (Orlando, USA)
 Stem cells for AD treatment – Involvement of cytokine in APP induced glial differentiation of stem cells
- 11:25 – 11:45 **Greg Brewer** (Springfield, USA)
 Reversing epigenetic aging in cell models of AD
- 11:45 – 12:05 **Amelia Marutle** (Stockholm, Sweden)
 Stimulating regenerative mechanisms in Alzheimer disease
 (*session partially supported by JSW-Lifesciences GmbH, Austria*)

12:05 – 13:30 Lunch

- 13:30 – 13:50 *State of the art lecture: Rudolf Tanzi* (Charlestown, USA)
 Novel Alzheimer disease genes and emerging biological pathways

Cerebrovascular Pathology: Cognitive Consequences and Preventive Strategies

Chairs: Theodor Landis and Gabriel Gold

- 13:50 – 14:10 **Gabriel Gold** (Geneva, Switzerland)
Mixed dementia: What have we learned from neuropathology?
- 14:10 – 14:30 **Philip Scheltens** (Amsterdam, The Netherlands)
Subcortical ischemic vascular disease: What have we learned from MRI studies?
- 14:30 – 14:50 **Amos Korczyn** (Ramat Aviv, Israel)
The vascular contribution to dementia
- 14:50 – 15:10 **Ingmar Skoog** (Göteborg, Sweden)
Subcortical ischemic vascular disease: A target for prevention and treatment in dementia disorders

15:10 – 15:40 Break

- 15:40 – 16:00 *State of the art lecture:* **Rodger Elble** (Springfield, USA)
Cerebrospinal fluid drainage in the treatment of dementia

Emerging Novel Therapeutic Targets II

Chairs: Beka Solomon and Harald Hampel

- 16:00 – 16:20 **Suzanne Craft** (Seattle, USA)
Intranasal insulin improves cognition and modulates beta-amyloid in early AD
- 16:20 – 16:40 **Harald Hampel** (Frankfurt, Germany)
Lithium trial in AD: A randomized, single-blinded, placebo-controlled multicentre 10-week study
- 16:40 – 17:00 **Andy Protter** (San Francisco, USA)
Dimebon (Latrepidine) – A therapeutic candidate for neurodegenerative diseases with a novel mechanism of action
- 17:00 – 17:20 **Beka Solomon** (Ramat Aviv, Israel)
A new target for AD immunotherapy: Beta secretase

(Session partially supported by Medivation, USA)

Saturday, March 27, 2010

Room A

- 08:15 – 08:35 *State of the art lecture:* **Constantin Bouras** (Geneva, Switzerland)
The brain of the centenarians

Moving to TAU: An Obligatory Step Towards a Disease-Modifying Treatment in AD

Chairs: Khalid Iqbal and Panteleimon Giannakopoulos

- 08:35 – 08:55 **Panteleimon Giannakopoulos** (Geneva, Switzerland)
The contribution of tau-related pathology in AD: What we really know?
- 08:55 – 09:15 **Khalid Iqbal** (Staten Island, USA)
From tangles to tau protein: Biomarker and therapeutic opportunities
- 09:15 – 09:35 **Eckhard Mandelkow** (Hamburg, Germany)
Tau and AD: From structure to transgenic mice and aggregation inhibitors
- 09:35 – 09:55 **Karen Duff** (New York, USA)
Pathogenic mechanisms and therapeutic approaches for the tauopathies

09:55 – 10:25 Break

- 10:25 – 10:45 *State of the art lecture:* **John Breitner** (Seattle, USA)
Bi-directional effect of naproxen on the pathogenesis of AD: Clinical and biological evidence
from a randomized primary prevention trial

Non Alzheimer Disease Dementias: Diagnostic Issues and Treatment

Chairs: Philippe Robert and Roberto Bernabei

- 10:45 – 11:05 **Bruno Dubois**, (Paris, France)
MCI: From the syndrome to the underlying disease
- 11:05 – 11:25 **Ian McKeith** (Newcastle, UK)
Improving diagnosis in dementia with Lewy bodies (DLB)

- 11:25 – 11:45 **Philippe Robert** (Nice, France)
Treating early behavioral and psychological symptoms of dementias
- 11:45 – 12:05 **Roberto Bernabei** (Rome, Italy)
Dementia and multimorbidity: The importance of comprehensive geriatric assessment and treatment

12:05 – 13:30 Lunch

- 13:30 – 13:50 *State of the art lecture:* **René Rizzoli** (Geneva, Switzerland)
Vitamin D and cognitive function

Oral Communications III

Chairs: Andreas Monsch and Armin von Gunten LS

- 13:50 – 14:05 TBA
- 14:05 – 14:20 TBA
- 14:20 – 14:35 TBA
- 14:35 – 14:50 TBA
- 14:50 – 15:05 TBA
- 15:05 – 15:10 Discussion

15:10 – 15:40 Closing remarks

19:00 – 22:30 Speakers dinner (by invitation)

Saturday, March 27, 2010

Room B

- 08:15 – 08:35 *State of the art lecture:* **Ezio Giacobini** (Geneva, Switzerland)
Why so few drugs for AD? The answer

Emerging Novel Therapeutic Targets III

Chairs: Michael Murphy

- 08:35 – 08:55 **Michael Murphy** (Beverly Hills, USA)
Coming full circle – Refined patient phenotypes in disease modification therapy
- 08:55 – 09:15 **Mene Pangalos** (Collegeville, USA)
Disease modifying approaches for the treatment of AD
- 09:15 – 09:35 **Pedro Pesini** (Zaragoza, Spain)
The use of A-beta C-terminal peptides in the early diagnosis and preventive treatment of AD
- 09:35 – 09:55 **Michal Novak** (Bratislava, Slovak Republic)
Can we develop an anti-tau immunization therapy?
(session partially supported by Araclon Biotech, Spain; Worldwide Clinical Trials, USA and Wyeth Pharmaceuticals, USA)

09:55 – 10:25 Break

Oral Communications I

Chairs: Reto Kressig and Frédéric Assal

- 10:25 – 10:40 **Vic Ramkumar** (Springfield, USA)
Protective role of adenosine A1 receptor against beta-amyloid neurotoxicity
- 10:40 – 10:55 **Taher Darreh-Shori** (Stockholm, Sweden)
Apolipoprotein E and A-beta may affect cholinergic neurotransmission
- 10:55 – 11:10 **Ildiko Szanto** (Geneva, Switzerland)
Aging related pathologies and oxidative stress

- 11:10 – 11:25 **Amy Arai** (Springfield, USA)
Modification of synaptic transmission and plasticity in AD-transgenic mice
- 11:25 – 11:40 **Nigel Greig** (Baltimore, USA)
GLP-1 Receptor stimulation as a treatment strategy for AD and neurodegenerative disorders
- 11:40 – 11:55 **Karl-Heinz Krause** (Geneva, Switzerland)
NOX inhibitors as novel therapeutics for the treatment of neurodegenerative diseases
- 11:55 – 12:05 General discussion

12:05 – 13:30 Lunch

- 13:30 – 13:50 State of the art lecture: **Ulrich Vischer** (Geneva, Switzerland)
Diabetes, the metabolic syndrome and Alzheimer disease

Oral Communications II

Chairs: Christophe Büla (LS) and Jean-Marie Annoni (GE)

- 13:50 – 14:05 **Ana Martinez** (Madrid, Spain)
Enhancing endogenous neurogenesis with GSK3 inhibitors as a new therapeutic strategy for AD
- 14:05 – 14:20 **Annalena Venneri** (Hull, UK)
Neuropsychological indicators of response to cholinesterase inhibitor treatment in early AD
- 14:20 – 14:35 **Jakub Hort** (Prague, Czech Republic)
Subgroups of mild cognitive impairment have identical spatial memory impairment as found in AD
- 14:35 – 14:50 **Luigia Trabace** (Foggia, Italy)
Soluble beta amyloid 1-42: A critical player in producing changes evoking depressive-related state?
- 14:50 – 15:05 TBA
- 15:05 – 15:10 Discussion

15:10 – 15:40 Closing remarks

19:00 – 22:30 Speakers dinner (by invitation)

Red: new – need to update

Orange: updated title (matching the abstract)